A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function - CV013-020
Updated: 03 December, 2018 | ClinicalTrials.gov
Print Friendly Summary
Detailed information regarding this trial is below, but the following may help determine if you are eligible.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less) - Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these medications in the past 2 weeks - Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10 pmol/L) Exclusion Criteria: - Systolic blood pressure (SBP) < 110 mm Hg at screening or pre-randomization - Heart rate < 50 beats per minute (bpm) or > 90 bpm at screening or pre-randomization - Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter - Estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2 - Ventricular assist device or prior heart transplant - Prior solid organ transplant - Body weight < 45 kg or ≥ 140 kg - Low quality echocardiographic visualization windows and image acquisition - Permanent paced rhythm (VVI, DDD or BiV pacing) Other protocol defined inclusion/exclusion criteria could apply